U.S. Department of Health and Human Services; National Institutes of Health; NIH News; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - Wednesday, August 13, 2008
CONTACT: Trish Reynolds, NIAMS, 301-496-8190, e-mail: Patricia.reynolds@nih.gov
Scientists at the National Institutes of Health (NIH) have found a mechanism in the immune systems of mice that can lead to the development of autoimmune disease when turned off. The findings shed light on the processes that lead to the development of autoimmunity and could also have implications for the development of drugs to increase the immune response in diseases such as cancer and HIV. The study paper appears online today in the journal "Nature."
The scientists from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Allergy and Infectious Diseases (NIAID), both part of the NIH, studied immune system T cells -- specifically the helper T cell, an immune system component that helps other cells fight infection. They focused on the protein furin, an enzyme that plays an important role in the functioning of T cells.
Scientists have been limited in their ability to study the protein furin, because other enzymes can perform some of the same functions. Also, furin is essential to life, so scientists have been unable to create a mouse without furin that lives past the embryo stage of development. Since the NIH scientists were unable to see what a mouse without furin would look like, they collaborated with Belgium scientists to create a mouse without furin only in T cells. What they discovered was that mice without furin in these cells developed systemic autoimmune disease. This means that the immune systems of the mice attacked their own cells and tissues throughout their bodies.
"We already know that furin seems to have roles in a variety of human diseases, such as cancer, cystic fibrosis and infectious diseases," says lead author Marko Pesu, Ph.D., in the NIAMS' Molecular Immunology and Inflammation Branch. "These findings show that having no furin in certain immune system cells can increase the immune response and lead to autoimmune disease in mice."
The researchers found that deleting furin in helper T cells affected the functioning of two types of T cells, regulatory and effector T cells. The former cells, also called Tregs, promote immune tolerance to the body's own cells and tissues. Upon further examination, the researchers found that mice lacking furin in Tregs had lower levels of a specific protein, TGF- 1, which is produced by these cells and is important for their ability to preserve immune tolerance. However, the researchers noted that effector T cells also produce TGF- 1. They found that furin is also needed for TGF- 1 production by effector T cells and that the absence of furin in effectors makes these cells more aggressive in causing autoimmune disease and tissue damage.
"Inhibiting furin has been thought to reduce growth of malignant cells or to block infections by preventing essential activation of a pathogen," says study author and NIAMS' Scientific Director John J. O'Shea, M.D., chief of the NIAMS' Molecular Immunology and Inflammation Branch. "However, these results suggest that the development of drug interventions could have an unexpected side effect of increasing the risk of developing autoimmune disease."
Investigators from the NIH's National Cancer Institute also contributed to this study.
For more information about autoimmune diseases, visit the Medline Plus Web site, a service of the NIH's National Library of Medicine, at <http://www.nlm.nih.gov/medlineplus/autoimmunediseases.html>
For more information about the NIAMS' Molecular Immunology and Inflammation Branch, visit the NIAMS Web site at <http://www.niams.nih.gov/Research/Ongoing_Research/Branch_Lab/Molecular_Immunology_and_Inflammation/default.asp>
For more information about cancer, please visit the NCI website at <http://www.cancer.gov>, or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at <http://www.niaid.nih.gov>.
The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the Department of Health and Human Services' National Institutes of Health (NIH), is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. For more information about NIAMS, call the information clearinghouse at 301-495-4484 or 877-22-NIAMS (free call) or visit the NIAMS Web site at <http://www.niams.nih.gov>.
The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <www.nih.gov>.
-----------------------------------------
REFERENCE: Marko Pesu, Wendy T. Watford, Lai Wei, Lili Xu, Ivan Fuss, Warren Strober, John Andersson, Ethan M. Shevach, Martha Quezado, Nicolas Bouladoux, Anton Roebroek, Yasmine Belkaid, John Creemers, & John J. O'Shea. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. "Nature" Advance Access published August 13, 2008, doi: 10.1038/nature07210.
PubMed link: Nature. 2008 Aug 13 [Epub ahead of print]
080813
NIH080802
Published 2008 - The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research. All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .